Sarepta Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas S. Ingram
- Full Time Employees
- 1,372
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 215 First Street Cambridge MA United States of America 02142
- IPO Date
- Jun 4, 1997
- CIK
- 0000873303
- Website
- sarepta.com
- Similar Companies
- Business
- Sarepta Therapeutics, Inc. (SRPT) is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare neuromuscular and central nervous system disorders, primarily Duchenne muscular dystrophy (DMD); its core products include FDA-approved RNA-targeted exon-skipping therapies EXONDYS 51 (eteplirsen) for exon 51 skipping, VYONDYS 53 (golodirsen) for exon 53 skipping, and AMONDYS 45 (casimersen) for exon 45 skipping, alongside the gene therapy ELEVIDYS (delandistrogene moxeparvovec-rokl) for DMD patients aged four and older with confirmed DMD gene mutations. The company advances a pipeline of over 40 programs across gene therapy, RNA technology including Morpholino oligomers and siRNA, and gene editing platforms, targeting DMD, limb-girdle muscular dystrophies (LGMDs), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), Huntington's disease, and other rare diseases; it serves patients, healthcare providers, and partners globally through manufacturing facilities and commercialization efforts. Founded in 1980 and headquartered in Cambridge, Massachusetts, with operations including a Genetic Therapies Center of Excellence in Columbus, Ohio, Sarepta targets pediatric and adult patients in the U.S. and select international markets via collaborations such as ex-U.S. rights with Roche. Recent developments include a November 2024 global licensing and collaboration agreement with Arrowhead Pharmaceuticals, providing Sarepta four clinical-stage siRNA programs for DM1, FSHD, and other neuromuscular indications plus three preclinical assets for $500 million upfront, $325 million in Arrowhead equity, and $50 million annual payments over five years, which closed in February 2025 and advanced with a $100 million milestone for the SRP-1003 DM1 program in August 2025. In June 2024, the FDA expanded ELEVIDYS approval to ambulatory and non-ambulatory DMD patients aged four and older, granting traditional approval for non-ambulatory use and accelerated approval for ambulatory; confirmatory ESSENCE study data for additional exon-skipping therapies was completed in Q3 2025, supporting planned supplemental NDA filings. Amid challenges including patient deaths linked to ELEVIDYS prompting a July 2025 restructuring with 36% workforce layoffs for $400 million in 2026 cost savings, and FDA clearance in November 2025 for a study mitigating liver injury risks, Sarepta reported Q3 2025 revenues boosted by $166.9 million in collaboration income from Roche-related milestones and Japanese approvals.
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
My Top 3 Biotech Stocks for May 2026
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?